Efficacy and safety of biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in insulin naive type 2 diabetic patients with secondary OHA [oral hypoglycaemic agent] failure

Trial Profile

Efficacy and safety of biphasic insulin aspart 30 [insulin aspart/insulin protamine aspart] in insulin naive type 2 diabetic patients with secondary OHA [oral hypoglycaemic agent] failure

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Insulin aspart/insulin protamine aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 May 2009 Actual patient number (71) added as reported by ClinicalTrials.gov.
    • 15 May 2009 Actual end date (Jan 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top